| 注册
首页|期刊导航|山东医药|原发CD5+弥漫大B细胞淋巴瘤的临床分析

原发CD5+弥漫大B细胞淋巴瘤的临床分析

臧立 王晓芳 李香丽 张小影 杨洪亮 赵海峰 于泳 王亚非 赵智刚 张翼鷟

山东医药Issue(37):12-14,3.
山东医药Issue(37):12-14,3.DOI:10.3969/j.issn.1002-266X.2015.37.004

原发CD5+弥漫大B细胞淋巴瘤的临床分析

Clinical analysis of CD5+diffuse large B-cell lymphoma

臧立 1王晓芳 1李香丽 1张小影 1杨洪亮 1赵海峰 1于泳 1王亚非 1赵智刚 1张翼鷟1

作者信息

  • 1. 天津医科大学肿瘤医院,国家肿瘤临床医院研究中心,天津市“肿瘤防治”重点实验室,天津300060
  • 折叠

摘要

Abstract

Objective To investigate the clinical features and immunophenotype of primary CD5+diffuse large B-cell lym-phoma (DLBCL) and to explore the treatment and prognosis.Methods The clinical data of 33 cases of CD5+DLBCL patients were retrospectively analyzed, The immunephenotype was detected by immunohistochemistry, and their relationship with clinico-pathological features was analyzed.Results There were 16 patients whose age was over 60 years, 19 cases of patients were in the Ann-Arbor stageⅢ-Ⅳ, and there were 3 cases of early onset of bone marrow involvement;IPI score ≥2 were found in 18 cases;CD5 and CD20 were expressed in all patients, and there were 18 cases of patients with positive Bcl-6 expression, 22 cases of Mum-1 positive expression.Both were not related with the patients'age, gender, Ann-Arbor stage, B symptoms and IPI scores (all P<0.05).Except that 5 cases gave up treatment, the majority of patients received the chemotherapy with cyclophospha-mide, doxorubicin, vincristine, CHOP or R-CHOP.The treatment efficacy evaluation were as follows:nine cases with complete remission, 13 cases with partial remission, 3 cases with stability and 3 cases in the progression.Twelve patients relapsed in two years or died in the disease progression, including 4 cases of central nervous system involvement and death.The median survival was 17.8 months, and 2-year overall survival rate was 53.9%.Conclusions Primary CD5+DLBCL is more common in older pa-tients with poor prognosis, and it is easy to have central and bone marrow involvement, with high degree of malignancy, mean-while, the efficacy of CHOP or R-CHOP is not good.Histopathological tissues are mostly from the non-germinal center.In addi-tion, the Bcl-6 and Mum-1 expression is not related with the clinicopathologic features and prognosis of CD 5+DLBCL.

关键词

弥漫大B细胞淋巴瘤/CD5+/免疫组织化学

Key words

diffuse large B-cell lymphoma/CD5+/immunohistochemistry/elderly female

分类

医药卫生

引用本文复制引用

臧立,王晓芳,李香丽,张小影,杨洪亮,赵海峰,于泳,王亚非,赵智刚,张翼鷟..原发CD5+弥漫大B细胞淋巴瘤的临床分析[J].山东医药,2015,(37):12-14,3.

基金项目

国家自然科学基金资助项目(1-3-98)。 ()

山东医药

OA北大核心CSTPCD

1002-266X

访问量4
|
下载量0
段落导航相关论文